Regulation of Gene Expression by 1
,25-Dihydroxyvitamin D3 and Its Analog EB1089 under Growth-Inhibitory Conditions in Squamous Carcinoma Cells
Naotake Akutsu1,
Roberto Lin1,
Yolande Bastien,
Alain Bestawros,
Danny J. Enepekides,
Martin J. Black and
John H. White
Departments of Physiology and Medicine (N.A., R.L., Y.B., A.B.,
J.H.W.) McGill University Montreal, Quebec H3G 1Y6, Canada
Department of Otolaryngology-Head and Neck Surgery (D.J.E.,
M.J.B.), and Montreal Center for Experimental Therapeutics in
Cancer (M.J.B., J.H.W.) Jewish General Hospital and McGill
University Montreal, Quebec, H3T 1E2, Canada
 |
ABSTRACT
|
---|
Analogs of 1
,25-dihydroxyvitamin
D3 (1
,
25(OH)2D3)
inhibit growth in vitro and in vivo of
cells derived from a variety of tumors. Here, we examined the effects
of 1
,25(OH)2D3 and
its analog EB1089 on proliferation and target gene regulation of human
head and neck squamous cell carcinoma (SCC) lines SCC4, SCC9, SCC15,
and SCC25. A range of sensitivities to
1
,25(OH)2D3 and
EB1089 was observed, from complete
G0/G1 arrest of SCC25
cells to only 50% inhibition of SCC9 cell growth. All lines expressed
similar levels of vitamin D3 receptor (VDR)
mRNA and protein, and no significant variation was observed in
1
,25(OH)2D3-dependent
induction of the endogenous 24-hydroxylase gene,
or of a transiently transfected
1
,25(OH)2D3-sensitive
reporter gene. The antiproliferative effects of
1
,25(OH)2D3 and
EB1089 in SCC25 cells were analyzed by screening more than 4,500 genes
on two cDNA microarrays, yielding 38 up-regulated targets, including
adhesion molecules, growth factors, kinases, and transcription factors.
Genes encoding factors implicated in cell cycle regulation were
induced, including the growth arrest and DNA damage gene, gadd45
,
and the serum- and glucocorticoid-inducible kinase gene, sgk. Induction
of GADD45
protein in EB1089-treated cells was confirmed by Western
blotting. Moreover, while expression of proliferating cell
nuclear antigen (PCNA) was reduced in EB1089-treated cells,
coimmunoprecipitation studies revealed increased association between
GADD45
and PCNA in treated cells, consistent with the capacity of
GADD45
to stimulate DNA repair. While
1
,25(OH)2D3 and
EB1089 modestly induced transcripts encoding the cyclin-dependent
kinase inhibitor p21waf1/cip1, no changes
in protein levels were observed, indicating that
p21waf1/cip1 induction does not contribute to
the antiproliferative effects of
1
,25(OH)2D3 and
EB1089 in SCC cells. Finally, in partially resistant SCC9 cells, there
was extensive loss of target gene regulation (10 of 10 genes
tested), indicating that resistance arises from widespread loss
of
1
,25(OH)2D3-dependent
gene regulation in the presence of normal levels of functional VDRs.
 |
INTRODUCTION
|
---|
The active form of vitamin D3,
1
,25-dihydroxyvitamin D3
[1
,25(OH)2D3]
modulates gene expression by binding to the vitamin
D3 receptor (VDR), which is a member of the
nuclear receptor family of transcriptional regulators.
1
,25(OH)2D3-bound VDR
heterodimerizes with retinoid X receptors (RXRs) and binds to specific
DNA sequences in target genes known as vitamin D3
response elements (VDREs) (1, 2). Apart from its well characterized
role in calcium homeostasis (3),
1
,25(OH)2D3 also
inhibits growth and stimulates differentiation of cancer cells derived
from a variety of tissues, including breast, prostate, colon, lung,
endometrium, hematopoietic cells, and oral cavity (4, 5, 6, 7, 8, 9, 10). A side
chain analog of
1
,25(OH)2D3,
EB1089, caused apoptotic regression of MCF-7 breast carcinoma
xenografts in nude mice (9), and animal studies and early clinical
testing have shown that therapeutic doses of EB1089 can be tolerated
without inducing hypercalcemia (10).
Analogs of 1
,25(OH)2D3 are
potential candidates for chemoprevention of squamous cell
carcinomas (SCCs) of the oral cavity, where formation of second primary
carcinomas after surgical removal of tumors is a major concern (11, 12). Retinoids, such as 13-cis retinoic acid
(13-cis-RA; isotretinoin) have been used clinically in SCC
chemoprevention (13). 13-cis-RA functions by binding to
retinoic acid receptors (RARs), which, like the VDR, are nuclear
receptors and function as heterodimers with RXRs (1). However, SCC
progression is associated with reduced expression of RARs, particularly
RARs ß and
, loss of retinoid-regulated differentiation markers,
and resistance to the antiproliferative effects of retinoids
(14, 15, 16, 17, 18, 19).
Here, we have examined the effect of
1
,25(OH)2D3 and EB1089
on proliferation and target gene regulation of four human SCC lines,
SCC4, SCC9, SCC15, and SCC25, which were derived from the floor of
mouth/base of tongue lesions (14). SCC25 cells express near normal
levels of RARs ß and
and retain retinoid regulation of keratin-19
(K-19) gene expression, whereas SCC4, SCC9, and SCC15 cells express
reduced levels of RAR
, no RARß, and have lost regulated K-19
expression (14). The SCC lines display differing sensitivities to
1
,25(OH)2D3 and EB1089.
SCC25 cell growth was completely blocked by
1
,25(OH)2D3 and EB1089,
while the other lines were partially resistant. We have identified 38
1
,25(OH)2D3 target genes
in SCC25 cells, which encode several components of signal transduction
pathways. Our results indicate that the antiproliferative effects of
1
,25(OH)2D3 and its
analogs are mediated by multiple downstream components. Moreover,
resistance to
1
,25(OH)2D3 in SCC9
cells was accompanied by widespread loss of target gene regulation in
spite of normal levels of functional VDRs.
 |
RESULTS
|
---|
Effect of
1
,25(OH)2D3 and
EB1089 on Growth of SCC Lines
The growth-inhibitory effects of
1
,25(OH)2D3,
EB1089, and 13-cis-RA were evaluated in human
lines SCC4, SCC9, SCC15, and SCC25, derived from SCCs of the oral
cavity. The four lines displayed different sensitivities to
1
,25(OH)2D3 or EB1089
(Fig. 1
). Over 10 days, SCC25 cell growth
was completely inhibited by 100 nM
1
,25(OH)2D3, and 1100
nM EB1089 (Fig. 1
, A and B), while SCC4, SCC9,
and SCC15 cells displayed partial resistance to both compounds (Fig. 1
, D, E, G, H, J, and K). Similarly, SCC25 cell growth was strongly
inhibited by 13-cis-RA (100 nM; Fig. 1C
), whereas growth of SCC4, SCC9, and SCC15 cells was partially
resistant (Fig. 1
, F, I, and L). Flow cytometric analysis showed that
treatment of SCC25 cells with 100 nM EB1089
for 72 h reduced the number of cells in S phase by 2.5-fold and
significantly increased the percentage in
G0/G1 (Fig. 2A
). No evidence for DNA fragmentation
was observed by terminal deoxynucleotidyltransferase
dUTP-biotin nick end-labeling (TUNEL) assays under these
conditions or over extended periods (Fig. 2B
).

View larger version (40K):
[in this window]
[in a new window]
|
Figure 1. Dose-Dependent Effects of
1 ,25(OH)2D3,
EB1089, and 13-cis-RA on Proliferation of SCC Lines in
Culture
SCC lines were treated with 1, 10, or 100 nM
1 ,25(OH)2D3 (A, D, G,
and J), 0.1, 1, 10, or 100 nM EB1089 (B, E, H,
and K), and 1, 10, or 100 nM 13-cis-RA
(C, F, I, and L). Media were changed and fresh ligand added every 2
days over the 10-day period of the experiment. Each point
represents the result obtained from triplicate wells (see
Materials and Methods for details).
|
|

View larger version (24K):
[in this window]
[in a new window]
|
Figure 2. Flow Cytometric Analysis and TUNEL Assay of Control
or EB1089-Treated SCC25 Cells
A, SCC25 cells were treated with vehicle (SCC25 cont) or EB1089 (SCC25
EB) for 72 h. A histogram of fractions of cells in
G0/G1, S, or G2 from three
independent experiments is presented. Statistical significance was
determined using Students t test. B, Representative
histograms of three experiments assessing 3'-OH end labeling
characteristic of apoptotic cells (TUNEL assay). Control cells and
cells treated for 72 h with 100 nM EB1089 display
minimal DNA fragmentation.
|
|
Resistance to
1
,25(OH)2D3 in SCC4,
SCC9, and SCC15 cells Is Not Accompanied by Loss of Expression of
Functional VDR
Given that resistance to 13-cis-RA correlated with lost
or reduced expression of RARs ß and
, respectively (14),
it was of interest to examine the levels of functional VDR in SCC
cells. Northern and Western blots showed that VDR transcript and
protein levels were essentially identical in all four lines (Fig. 3
, A and B). Similarly, no evidence was
found for loss of expression of the two major RXRs expressed in SCC,
RXR
and RXRß (data not shown). VDR function was tested by
transient transfection of a
1
,25(OH)2D3-sensitive
reporter-promoter plasmid containing a bacterial lacZ gene under
control of a synthetic promoter containing three VDREs (20). High
levels of
1
,25(OH)2D3-inducible
ß-galactosidase activity were detected in all cell extracts (Fig. 4A
), suggesting that the lines expressed
similar levels of functional VDRs. Both
1
,25(OH)2D3 and EB1089
induced similar levels of expression of the endogenous 24-hydroxylase
(24-OHase) gene (Fig. 4B
), whose promoter contains VDREs (21).
Moreover, EB1089 induced 24-OHase expression with essentially identical
potencies in
1
,25(OH)2D3-sensitive
SCC25 cells and the partially resistant lines SCC4 and SCC9 (Fig. 4C
).
Taken together, the results of Figs. 3
and 4
suggest that
resistance to
1
,25(OH)2D3 does not
arise through loss of expression of functional VDRs.

View larger version (82K):
[in this window]
[in a new window]
|
Figure 3. Expression of VDR Transcripts and Protein in SCC
Lines
A, Northern analyses are presented of transcripts encoding the VDR in
SCC lines, along with GAPDH controls. B, Western blots are presented of
VDR and ß-actin protein levels in SCC lines.
|
|

View larger version (55K):
[in this window]
[in a new window]
|
Figure 4. Assessment of VDR Function in SCC Lines
A, Cells were transfected with the
1 ,25(OH)2D3-sensitive reporter plasmid
VDRE3-hsp68-lacZ and treated with vehicle or 10 nM
1 ,25(OH)2D3 for 24 h (see
Materials and Methods for details). Data are presented
as fold induction of lacZ expression observed in the presence of
1 ,25(OH)2D3. B, Induction of endogenous
24-OHase gene expression by 1 ,25(OH)2D3 or
EB1089 in SCC lines. Northern blots of total RNA extracted from cells
treated for 24 h with vehicle (-),
1 ,25(OH)2D3-, or EB1089-treated cells are
presented. C, Dose-dependence of 24-hydroxylase induction in
1 ,25(OH)2D3-sensitive SCC25 cells and
partially resistant SCC4 and SCC9 cells. Northern blots of 24-OHase and
ß-actin controls are presented above, along with the normalized
results of densitometric scanning of the 24-OHase blots below.
|
|
Effects of
1
,25(OH)2D3 and
EB1089 on Cell Cycle Regulators in SCC25 Cells
We were interested in analyzing the mechanisms
underlying the antiproliferative effects of
1
,25(OH)2D3 and EB1089
in SCC25 cells. Previous work has shown that
1
,25(OH)2D3 rapidly (4
h) and strongly stimulated expression of the cyclin-dependent kinase
inhibitor genes p21waf1/cip1 and
p27kip1 in myeloid leukemia cells under
conditions where it induced differentiation and inhibited cell growth
(4, 22). However, the magnitude of the effect of
1
,25(OH)2D3 on
p21waf1/cip1 expression varies widely in
different cell lines (4, 6, 22, 23, 24). We found that
1
,25(OH)2D3- or
EB1089-dependent induction of p21waf1/cip1
transcripts in SCC25 cells was gradual and modest (Fig. 5A
and data not shown), whereas no
effect was observed on expression of p27kip1 or
p53 mRNA levels (Fig. 5B
). The modest effect of
1
,25(OH)2D3 and EB1089
on p21waf1/cip1 mRNA levels did not give rise to
significant changes in p21waf1/cip1 protein,
however. In addition, no effect of
1
,25(OH)2D3 or EB1089
was observed on p27kip1 protein levels (Fig. 5C
).

View larger version (71K):
[in this window]
[in a new window]
|
Figure 5. EB1089-Inducible Expression of
p21waf1/cip1, but Not p27kip1 or p53, in SCC25
Cells
A, The effect of EB1089 on expression in SCC25 cells of
p21waf1/cip1and a GAPDH control were analyzed by Northern
blotting of 20 µg of total RNA from cells treated with 10
nM 1 ,25(OH)2D3 for the
times indicated. B, The effect of EB1089 on expression in SCC25 cells
of p27kip1 and p53 along with a ß-actin control was
analyzed by RT-PCR. Amplified products were probed with
32P-labeled internal oligonucleotides as detailed in
Materials and Methods. C, Western blotting of
immunoprecipitates of p21WAF1/CIP1 and p27KIP1
from SCC25 cells treated for 48 h with vehicle (-), or 100
nM 1,25-(OH)2D3 (D3) or EB1089
(EB).
|
|
Identification of Target Genes of
1
,25(OH)2D3 and
EB1089 by Screening of cDNA Microarrays
We screened cDNA microarrays for novel target genes of
1
,25(OH)2D3 and EB1089
in SCC25 cells to identify factors mediating their
antiproliferative effects. More than 4,500 genes on two different gene
arrays [Atlas array, 588 genes; (CLONTECH Laboratories, Inc., Palo Alto, CA); Named Genes filter, 4,000+ genes
(Research Genetics, Inc., Huntsville, AL)] were screened
with probes derived from vehicle-treated cells or cells treated with
EB1089 for 24 h. Previous work has shown that there is
considerable variation in gene expression levels associated with
screening gene arrays (25, 26, 27, 28). Arrays were therefore screened multiple
times, and only reproducibly regulated genes were retained. Two rounds
of screening of Atlas arrays yielded 10 candidate genes, of which 6
were revealed by Northern blotting to be regulated by
1
,25(OH)2D3 and EB1089
(Fig. 6A
, and data not shown; Table 1
). In addition to
p21waf1/cip1 (not shown), these included novel
target genes amphiregulin, a member of the epidermal growth factor
family, the transcription factor fos-related antigen-1 (fra-1), the
growth arrest and DNA damage (gadd45
) gene, and integrin
7B. We
also found that the vascular endothelial growth factor (VEGF), which
has been shown to be a
1
,25(OH)2D3 target gene
in osteoblast-like cells (29, 30), was regulated by EB1089 in SCC25
cells.

View larger version (88K):
[in this window]
[in a new window]
|
Figure 6. Northern Analysis of EB1089-Regulated Target Gene
Expression
A, Northern analyses of target genes identified using a CLONTECH Laboratories, Inc. Atlas array. Transcripts expressed in SCC25
cells encoding amphiregulin (amphireg.), GADD45 , FRA-1, integrin
7B, and VEGF are shown. Cells were treated with vehicle (left
lane) or 10 nM EB1089 (right
lane) for 24 h, and 1 µg of poly A+ RNA was loaded on
each lane. B, Northern analyses, performed as in panel A, of target
genes identified using a Research Genetics, Inc. gene
filter, as follows: GAP SH3 BP, GAP SH3 binding protein; STAT3; UVRAG,
UV resistance-associated gene; calmodulin; ERM BPP50,
ezrin-radixin-meoisin binding phosphorprotein-50; ARP3, actin-related
protein 3; OTK27; RAB-1A, ras-related protein 1A; SGK, serum- and
glucocorticoid-inducible kinase; Retinobl BP3, retinoblastoma binding
protein 3. C, Northern analysis of target gene regulation in SCC9
cells. Cells were treated and blots were performed as in panel A. Note
that GAPDH controls were performed for blots in AC and showed no
significant variations (not shown).
|
|
Initial analysis of Research Genetics, Inc. gene filters
screened with duplicate preparations of probe from vehicle-treated
cells revealed a substantial number of differentially expressed genes
(data not shown), which likely corresponded to random fluctuations in
gene expression observed in expression profiling (25, 26, 27, 28). Therefore,
filters were screened three times each with probe from independent
preparations of vehicle- and EB1089-treated cells, generating nine sets
of cross-comparisons. Genes that were reproducibly regulated at least
1.5-fold in all comparisons were conserved. This yielded 32 additional
up-regulated genes representing several different classes of proteins
(Table 1
). Screening under these conditions did not reveal any
reproducibly down-regulated genes. Up-regulated genes included
calmodulin, which has previously been shown to be a
1
,25(OH)2D3 target gene
(31). Northern blotting, used to further test expression of 10 of these
genes, revealed EB1089-stimulated expression in all cases (Fig. 6B
),
indicating that the data in Table 1
are highly reliable. Most of the
genes retained from phosphorimager analysis of the Research Genetics, Inc. arrays were up-regulated 2- to 4-fold (Table 1
).
This range of induction agrees well with that of up-regulated targets
identified in a similar screen of thyroid hormone-regulated genes
(33).
Broad but Selective Loss of Target Gene Expression in
1
,25(OH)2D3-Resistant
SCC Lines
Given the resistance of SCC9 cells to the inhibitory effects of
1
,25(OH)2D3 and EB1089,
we analyzed the regulation of target genes in these cells. Remarkably,
in spite of apparently normal induction of 24-OHase expression (Fig. 4
), regulation of all of the target genes tested in SCC9 cells was
either lost, or in the case of calmodulin and GAP SH3 binding protein,
attenuated (Fig. 6C
). These results provide a strong correlation
between increased resistance to the antiproliferative effects of
1
,25(OH)2D3 and a broad
but selective loss of
1
,25(OH)2D3 target gene
regulation in the presence of apparently normal levels of functional
VDR.
EB1089 Treatment Induces Expression of GADD45
Protein and
Enhances Formation of GADD45
-Proliferating Cell Nuclear Antigen
(PCNA) Complexes
One of the more intriguing genes identified
from the array screening presented above was gadd45
(Fig. 6
and
Table 1
). Gadd45
is a p53 target gene induced by a variety of agents
that damage DNA and arrest cell growth (33, 34, 35, 36), and overexpression of
GADD45
inhibits cell proliferation (34). Ablation of the gadd45
gene provided evidence that GADD45
functions to maintain global
genomic stability (35). Peak expression of GADD45
occurs in
G1. DNA repair is enhanced at the
G1/S checkpoint, and several studies have
suggested that GADD45
enhances DNA repair, at least in part, through
its interaction with PCNA (36, 37, 38).
Induction of gadd45
mRNA by EB1089 was only partially blocked by
protein synthesis inhibitor cycloheximide (Fig. 7A
, and data not shown), indicating that
the effect of EB1089 is at least partially direct. In related studies,
we found no effect of cycloheximide on induction of gadd45
transcripts by EB1089 in the mouse SCC line AT-84 (38A ).
Immunoprecipitations from control and treated SCC25 cells revealed that
EB1089 induced expression of GADD45
protein (Fig. 7B
), consistent
with its effects on gadd45
mRNA levels. Previous studies have
demonstrated that
and UV irradiation induce GADD45
and enhance
its interaction with PCNA (36, 37). It was therefore of interest to
determine whether a similar interaction was induced by EB1089, which is
not a DNA damaging agent. While EB1089 treatment of SCC25 cells
consistently reduced expression of PCNA protein (Fig. 7B
and data not
shown), reciprocal coimmunoprecipitations revealed an increased
association between PCNA and GADD45
in EB1089-treated cells (Fig. 7B
). Thus, 1
,25(OH)2D3
analog EB1089 induces expression of GADD45
, leading to increased
formation of GADD45
-PCNA complexes. Taken together, our results
suggest that induction of GADD45
contributes to the
growth-inhibitory effects of
1
,25(OH)2D3 and EB1089
in SCC25 cells.
 |
DISCUSSION
|
---|
The results presented above show that
1
,25(OH)2D3 and EB1089
were as or more potent, respectively, than 13-cis-RA in
inhibiting growth of SCC25 cells in culture. SCC4, SCC9, and SCC15
cells were partially resistant to 13-cis-RA and to
1
,25(OH)2D3 and EB1089
(Fig. 1
), raising the possibility of a common underlying
mechanism of resistance. Expression of RARs ß and
is lost or
reduced, respectively, in SCC4, SCC9, and SCC15 cells (14). However, no
evidence was found for loss of VDR expression or function in these
lines. No substantial differences were observed in induction of
endogenous 24-hydroxylase gene expression, the transcription of which
is controlled by a VDRE-containing promoter (21), or of a transiently
transfected VDRE3-hsp68/lacZ reporter plasmid. This is consistent with
other findings suggesting that VDR levels vary little among SCC lines,
including SCC4 (39, 40). Our results showed that VDRs expressed in all
four lines studied retained the capacity to activate transcription from
VDRE-containing promoters. We have also characterized a mouse SCC line,
AT-84, which is highly sensitive to
1
,25(OH)2D3 and EB1089
but resistant to the growth- inhibitory effects of retinoids
(38A ), showing that resistance to
1
,25(OH)2D3 and
retinoids is not necessarily coupled.
Several results suggest that many factors contribute to the
growth-inhibitory effects of
1
,25(OH)2D3 in a
cell-specific manner. Transcripts encoding the cyclin-dependent kinase
inhibitors p21waf1/cip1 and
p27kip1 were strongly and rapidly
up-regulated by
1
,25(OH)2D3 in
myeloid leukemia cells, and forced expression of
p21waf1/cip1 induced myeloid cell differentiation
(4, 22). Moreover, a VDRE that functioned in U937 cells was identified
in the p21 promoter (4). However, the effect of
1
,25(OH)2D3 on
p21waf1/cip1 and p27kip1
expression is highly cell specific. The induction of
p21waf1/cip1 mRNA by EB1089 in SCC25 cells was
gradual and modest, but no effect on protein levels was observed (Fig. 5
). 1
,25(OH)2D3
treatment modestly increased p21waf1/cip1 protein
in LNCaP prostate cancer cells (23). However, no significant effect on
transcript levels and no
1
,25(OH)2D3-dependent
induction of the p21waf1/cip1 promoter was
observed in gene transfer experiments in LNCaP cells (23). Hershberger
et al. (6) found that
1
,25(OH)2D3 repressed
p21waf1/cip1 expression in the mouse SCCVII/SF
line, and we have observed a similar repression of
p21waf1/cip1 transcripts and protein in the mouse
SCC line AT-84 (38A ).
The lack of induction of cyclin-dependent kinase inhibitors in
1
,25(OH)2D3- or
EB1089-treated SCC25 cells led us to screen gene arrays to identify
other regulated genes in SCC25 cells. A total of 38 target genes,
including p21waf1/cip1, were identified in two
screens of more than 4,500 genes (Table 1
). The 32 targets identified
on the Research Genetics, Inc. filter were retained after
9 sets of cross- comparisons of data derived from screening with probe
derived from vehicle- and EB1089-treated SCC25 cells, using a minimum
induction of 1.5-fold as a cut-off. We confirmed that 10 of 10
candidates analyzed by Northern blotting showed
1
,25(OH)2D3-regulated
expression (Fig. 6
), indicating that the data obtained from the array
screening are highly reliable. Most genes were up-regulated 2- to
4-fold, a range in good agreement with that of up-regulated targets
identified in a similar screen of thyroid hormone- regulated genes
(33), and generally more modest than the levels of gene regulation
observed by forced overexpression of the tumor suppressor genes BRCA1
(41) and WT1 (42).
The genes identified in this study encode several different classes of
proteins, many of which are components of different signal transduction
pathways. They include cell adhesion proteins (e.g.
galectin-2, integrin
7B), growth factors (e.g.
amphiregulin, VEGF), cytoskeletal proteins (e.g.
actin-related protein 3), protein kinases (e.g. serum- and
glucocorticoid-regulated kinase, sgk), other intracellular signaling
molecules, and transcription factors (AP-4, STAT-3, FRA-1). Some of the
genes identified here have been implicated in regulation of the cell
cycle and growth arrest. One example is serum- and
glucocorticoid-inducible kinase, SGK, which is shuttled between the
nucleus and the cytoplasm during the cell cycle. Its forced retention
in either compartment suppressed serum-induced growth and DNA synthesis
in mammary tumor cells (43).
We also found that
1
,25(OH)2D3 and EB1089
induced expression of gadd45
, which like
p21WAF1/CIP1 is a p53 target gene. However,
neither compound affected p53 expression in SCC25 cells. A similar
induction of GADD45
expression by
1
,25(OH)2D3 and EB1089
was observed in vitro and in vivo in the murine
SCC line AT-84 under conditions in which expression of p53 was
unaffected and p21WAF1/CIP1 was repressed.
In contrast, DNA damaging agents induced p53,
p21WAF1/CIP1, and GADD45
in AT-84 cells
(38A ). Taken together, these results suggest that
1
,25(OH)2D3- and
EB1089-dependent induction of gadd45
occurs by a p53-independent
mechanism.
Consistent with its effects on gadd45
mRNA, EB1089 treatment of
SCC25 cells enhanced expression of GADD45
protein and stimulated
formation of GADD45
-PCNA complexes. Previous studies have shown that
DNA damaging agents, such as
or UV irradiation, induce formation of
GADD45
-PCNA complexes (36, 37). Induction of GADD45
-PCNA
complexes by EB1089, which is a growth inhibitor, but not a DNA
damaging agent, indicates that increased DNA damage is not
necessary to induce complex formation.
PCNA function is required for DNA replication in S phase, and for DNA
repair through its association with polymerases
and
(44).
Association of GADD45
with PCNA is considered to divert PCNA from
sites of DNA replication to sites of DNA repair. GADD45
modifies DNA
accessibility on damaged chromatin and can stimulate DNA repair
in vitro (36, 45, 46). In addition, DNA damaging agents
induce changes in the nuclear distribution of PCNA (47). It should be
noted, however, that PCNA also interacts with a number of other
regulatory proteins, including p21WAF1/CIP1 (48),
at sites that overlap those recognized by GADD45
(49). The relative
roles and importance of interactions of
p21WAF1/CIP1 and GADD45
with PCNA remain to be
fully elucidated. Nonetheless, the induction of GADD45
expression
and its central role in enhancing DNA repair suggest that treatment of
SCC cells with
1
,25(OH)2D3 or EB1089
would provide a genoprotective effect. This would be an important
characteristic of a potential chemopreventive agent.
The observation that
1
,25(OH)2D3 induced
expression of VEGF in SCC cells was surprising given that increased
VEGF levels are associated with tumor vascularization and tumor
progression (50). Elevated VEGF levels have been correlated with a
higher rate of disease recurrence and a shorter disease-free interval
in SCC of the oral cavity (51). These results highlight the complexity
of cellular responses to growth regulators such as
1
,25(OH)2D3 and its
analogs, where a combination of regulatory signals is induced under
conditions in which the overall effect of
1
,25(OH)2D3 is growth
inhibitory. It should also be noted that
1
,25(OH)2D3-regulated
expression of VEGF is highly cell specific. We did not observe any
induction of VEGF expression in MCF-7 and MBA-MD231 breast cancer or
LNCaP prostate cancer cells (data not shown), whereas others have shown
that VEGF expression is regulated by
1
,25(OH)2D3 in
osteoblast-like cells (29, 30).
The partial resistance of SCC9 cells to the growth-inhibitory effects
of 1
,25(OH)2D3
correlated with broad deregulation of target gene expression (10 of 10
genes tested). It is unlikely that loss of regulation arises through
repressed expression due to target gene methylation, since transcripts
of all genes refractory to
1
,25(OH)2D3 were
detected in vehicle-treated SCC9 cells (Fig. 6
). It is possible that
1
,25(OH)2D3-dependent
induction of these genes requires synergism of the VDR with other
transcription factor(s) or downstream regulators, the function of which
is defective in SCC9 cells. Such factors would not be required for
regulated expression of the endogenous 24-hydroxylase gene or the
synthetic VDRE3-hsp68 promoter. One possible candidate is AP1, whose
function is enhanced by
1
,25(OH)2D3 signaling
(52, 53, 54). However, this enhancement apparently requires, at least in
part, up-regulation of expression of AP1 components, particularly
c-jun. We have also found here that
1
,25(OH)2D3 modestly
up-regulates fra-1 mRNA levels. This suggests that if loss of induced
AP1 activity contributes to deregulation of
1
,25(OH)2D3 target gene
expression in resistant SCC lines, it may not be a primary defect. It
should also be noted that we have tested the effect of cycloheximide on
the six target genes identified on the Atlas array,
p21waf1/cip1, amphiregulin, VEGF, fra-1,
gadd45
, and integrin
7B, and found in each case there was no
effect on
1
,25(OH)2D3-stimulated
expression (Fig. 7
, and data not shown). Therefore, in these instances,
the stimulatory effect of
1
,25(OH)2D3 did not
require protein synthesis. Moreover, with the exceptions of integrin
7B and fra-1, which were not tested, regulation of all of these
genes was lost in SCC9 cells (Fig. 6
).
In summary, our studies have shown that
1
,25(OH)2D3
analogs can be potent inhibitors of SCC proliferation and control the
expression of several regulators of cell proliferation. However,
partial resistance to
1
,25(OH)2D3 can arise
even in the presence of apparently normal levels of functional VDR.
Resistance arises from a broad, but selective, loss in
1
,25(OH)2D3-regulated
gene expression in the presence of normal levels of functional
VDRs.
 |
MATERIALS AND METHODS
|
---|
Plasmids and Reagents
The VDRE3-hsp68-lacZ reporter contains three VDREs (20),
inserted upstream of minimal hsp68 promoter in the plasmid p610AZ (55).
The plasmid tk-LUC contains a truncated Herpes Simplex Virus thymidine
kinase promoter inserted upstream of a promoterless luciferase reporter
gene in pXP1 (56). 1
,25(OH)2D3 and EB1089 were
kindly supplied by Dr. Lise Binderup (Leo Laboratories, Ballerup,
Denmark). 13-cis-RA was purchased from ICN Biochemicals, Inc. (Costa Mesa, CA). All hormones were
dissolved in dimethylsulfoxide (DMSO), and stock solutions were stored
in the dark at -20 C.
Tissue Culture
The SCC lines, SCC4, SCC9, SCC15, and SCC25, obtained from the
American Type Culture Collection (ATCC,
Manassas, VA), were cultured under recommended conditions. Effects of
1
,25(OH)2D3, EB1089, and
13-cis-RA on cell growth were analyzed by seeding cells in
6-well plates at 15,000 cells per well in 2 ml of culture medium
containing charcoal-stripped serum. Media were changed after 24 h
to charcoal-stripped medium containing vehicle or ligand as indicated.
Media were changed every 48 h and fresh ligand added. Cells were
harvested by washing with 2 ml of PBS and incubation with 0.7 ml of
0.25% trypsin-EDTA. Cell numbers were determined using a
hemacytometer. Four grid sections were counted for each well and the
results were averaged. All treatments were performed in triplicate.
Transient Transfections
SCC cells were grown to 60% confluency in six-well plates in
charcoal-stripped medium, washed with 2 ml of Opti-MEM I-reduced serum
media (Life Technologies, Inc., Burlington, Ontario,
Canada), and cultured in 1 ml of Opti-MEM I. Cells were transfected
with 500 ng of VDRE3-LacZ reporter plasmid and 500 ng of tk-LUC
internal control using Lipofectin (Life Technologies, Inc.) according to the manufacturers protocol. After 18 h
media were replaced with charcoal- stripped medium containing ligands
as indicated. Cells were lysed 24 h later using lysis buffer
(Promega Corp., Madison, WI), and ß-galactosidase assays
were performed as described (57). Transfections were performed in
triplicate and standardized using the Luciferase Assay System with
reporter lysis buffer (Promega Corp.).
RNA Isolation and Northern Blotting
Cells were grown in 100-mm dishes. Media were replaced with
charcoal-stripped medium containing ligand as indicated. Total RNA was
extracted with TRIZOL (Life Technologies, Inc.). PolyA+
RNAs were isolated using an Oligotex mRNA Kit (QIAGEN,
Valencia, CA). One microgram of polyA+ RNA was separated on a 1.0%
agarose gel containing 6.3% formaldehyde, 20 mM
3-(N-morpholino)propanesulfonic acid (pH 7.0), 15
mM sodium acetate, and 1 mM
EDTA. Separated RNAs were transferred to a Nylon membrane (Hybond-N+,
Amersham Pharmacia Biotech, Baie dUrfe, Quebec), which
then was soaked in 3xsaline-sodium citrate (SSC) and 0.1% SDS
at 50 C, and prehybridized at 42 C in 50 mM
phosphate buffer, pH 6.5, 50% formamide, 5x SSC, 10% Denhardts
solution containing 250 µg/ml sheared, denatured salmon sperm DNA.
Hybridization was carried out in the same solution by the addition of
32P-labeled cDNA probes. Membranes were washed
four times in 2xSSC and 0.2% SDS for 5 min, three times in 0.1xSSC
and 0.2% SDS for 30 min at 50 C, dried, and autoradiographed. All
blots were performed at least three times with independent preparations
of RNA.
RT-PCR
Ten micrograms of total RNA were subjected to oligo dT priming
first-strand cDNA synthesis by SuperScript II (Life Technologies, Inc., Burlington, Ontario, Canada). Twenty microliter aliquots
were diluted 5-fold with water. For RT-PCR analysis of p53 and p27
kip1 mRNA, expression of 1 µl of RT reactions
was analyzed by PCR amplification as follows: 30 sec denaturation at 94
C, 45 sec elongation at 72 C, and 30 sec annealing starting at 60 C,
down 1 C per cycle to 55 C, and continuing 20 cycles of amplification
(94 C for 30 sec, 57.5 C for 30 sec, 72 C for 45 sec). Complementary
DNAs for p53 and p27 kip1 were
amplified using 5'-primer 5'-CAAGTCTGTGACTTGCACGTA-3' and 3'-primer
5'-TTCTTGCGGAGATTCTCTTCC-3' for p53, and 5'-primer
5'-CCGGAATTCATGTCAAACGTGCGAGTGTCT-3' and 3'-primer
5'-CCGGAATTCTTACGTTTGACGTCTTCTGAGGC-3' for
p27kip1. For ß-actin, 1 µl of RT reaction was
subjected to 18 cycles of amplification (95 C for 30 sec, 56 C for 1
min, 72 C for 25 sec) using 5'-primer 5'-GCTGTGCTATCCCTGTACGC-3' and
3'-primer 5'-CCAATGGTGATGACCTGGC-3'. All of the above reactions were
performed in 25 µl of 1.5 mM MgCl2,
50 mM KCl, and 10 mM Tris-Cl (pH 9.0) using 2.5
U of Taq DNA polymerase (Amersham Pharmacia Biotech, Baie dUrfe, Quebec, Canada). PCR reactions were
loaded on a 2% agarose gel, transferred for Southern blotting to a
nylon membrane (Hybond N+, Amersham Pharmacia Biotech),
and fixed by UV cross-linker. The membrane was soaked in 3x SSC and
0.1% SDS at 50 C, and prehybridized at 42 C in 50
mM phosphate buffer, pH 6.5, 5x SSC, 10%
Denhardts solution containing 250 µg/ml sheared and denatured
salmon sperm DNA. Hybridization was carried out in the same solution by
the addition of 32P end-labeled oligonucleotides
5'-CTACAAGCAGTCACAGCACAT-3' for p53, 5'-CTAACTCTGAGGACACGCATT-3' for
p27kip1, and 5'-CGAGAAGCTGTGCTACGTCG-3' for
ß-actin. After hybridization, the membrane was washed four times in
2x SSC and 0.2% SDS for 5 min, three times in 0.1x SSC and 0.2% SDS
for 30 min at 50 C, dried, and autoradiographed. All experiments were
repeated at least three times.
Immunoprecipitation and Western Blotting
After incubation with ligands, cells were washed twice with PBS
and harvested by scraping in 1 ml of PBS and centrifuged at 4 C. The
pellet was resuspended in 500 µl of ice-cold lysis buffer (10
mM Tris-HCl, pH 8.0, 60 mM KCl, 1
mM EDTA, 1 mM dithiothreitol, 0.5%
NP40) containing protease inhibitor cocktail (Roche Molecular Biochemicals, Mannheim, Germany), incubated on ice for 10 min.
Lysates were centrifuged at 4 C (14,000 rpm, 10 min), and supernatants
were recovered. For p21WAF1/CIP1 and
p27KIP1 immunoprecipitations, protein extracts
(200 µg) were immunoprecipitated at 4 C overnight with 3 µg of F-5
and F-8 anti-p21WAF1/CIP1 and
-p27KIP1 monoclonal antibodies, respectively
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) using 30
µl of 50% slurry protein S-Sepharose (Amersham Pharmacia Biotech). Beads were centrifuged, and pellets were washed four
times each with lysis buffer and boiled for 3 min in 2x
SDS-polyacrylamide gel loading buffer. Immunoprecipitates were resolved
on 20% SDS-polyacrylamide gels and analyzed by Western blotting with
the same antibodies. Immunoprecipitations of GADD45
and PCNA were
performed with anti-GADD45
antibody 4T-27 or with anti-PCNA antibody
PC-10 (Santa Cruz Biotechnology, Inc.). Immunoprecipitates
were harvested, processed for Western blotting as above and probed with
anti-GADD45 antibody (H-165) (Santa Cruz Biotechnology, Inc.) or with anti-PCNA (PC-10) (Santa Cruz Biotechnology, Inc.).
Western analysis of VDR expression was performed with 30 µg of total
cell protein resolved on a 15% SDS-polyacrylamide gel. VDRs were
probed with 800 ng of a rabbit polyclonal anti-VDR antibody
(Santa Cruz Biotechnology, Inc.). Proteins were detected
by enhanced chemiluminescence (ECL; NEN Life Science Products, Boston, MA).
Flow Cytometry and TUNEL Assays
SCC25 cells treated with 100 nM EB1089 or DMSO for
72 h were harvested with 0.25% trypsin-EDTA, fixed with 70%
ethanol for 1 h at 4 C, treated with 200 µg/ml RNase A for 30
min, stained with 5 µg/ml propidium iodide for DNA, and analyzed for
cell cycle status by flow cytometry (Becton Dickinson and Co., Franklin Lakes, NJ). Experiments were repeated three times.
TUNEL assays were performed using an Apoptag kit
(Intergen, Purchase, NY) according to the manufacturers
instructions. Briefly, after incubation with vehicle or ligand, cells
were fixed for 15 min in 1% paraformaldehyde, washed twice with PBS,
and stored in 70% ethanol at -20 C. Cells (100 µl) were then
incubated for 30 min at 37 C with terminal deoxynucleotidyl transferase
and digoxigenin-dUTP. After two washes with 0.1% Triton X-100 in PBS,
cells were incubated with fluorescein-conjugated antidigoxigenin
antibody for 30 min at room temperature. After two washes with 0.1%
Triton X-100 in PBS, cells were treated with RNase A and processed for
flow cytometry as above.
Array Screening
SCC25 cells were treated for 24 h with DMSO or EB1089 (100
nM). Atlas cDNA Expression Arrays containing 588 genes
(CLONTECH Laboratories, Inc. Palo Alto, CA) were screened
with 100 ng of polyA+ RNA. GF211 Named Human Genes arrays containing
more than 4,000 genes (Research Genetics, Inc.) were
probed with 1 µg of total RNA. Probe preparation and array screening
were carried out according to manufacturers instructions. Duplicate
Atlas arrays were screened twice each with probe derived from control
or treated cells and arrays were visualized by autoradiography. Genes
that appeared reproducibly regulated were studied by Northern analysis.
GF211 filters were probed three times each with probe derived from
control cells and EB1089-treated cells, and visualized by
phosphorimaging. Relative expression levels were compared using
Pathways software (Research Genetics, Inc.). Genes that
were up-regulated at least 1.5-fold in nine sets of cross-comparisons
were retained. Of these, 10 were further analyzed by Northern analysis
using cDNA probes from Research Genetics, Inc.
 |
ACKNOWLEDGMENTS
|
---|
We thank Dr. Lise Binderup (Leo Laboratories, Ballerup, Denmark)
for the generous gift of EB1089.
 |
FOOTNOTES
|
---|
Address requests for reprints to: Dr. John H. White, Department of Physiology, McGill University, McIntyre Medical Sciences Building, 3655 Drummond Street, Montreal, Quebec H3G 1Y6, Canada. E-mail:
jwhite{at}med.mcgill.ca
This work was supported by an operating grant from the Canadian
Institutes of Health Research (MT-15160) to J.H.W. Initial experiments
were supported by funds from the Department of Otolaryngology of the
Jewish General Hospital, Montreal. N.A. was supported by a postdoctoral
fellowship from the Royal Victoria Research Institute. J.H.W is a
chercheur-boursier of the Fonds de Recherche en Santé du
Québec (FRSQ).
1 N.A. and R.L. should be considered as equal first authors. 
Received for publication September 19, 2000.
Revision received February 26, 2001.
Accepted for publication March 13, 2001.
 |
REFERENCES
|
---|
-
Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G,
Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The
nuclear receptor superfamily: the second decade. Cell 83:835839[Medline]
-
Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson
PD, Selznick SH, Dominguez CE, Jurutka PW 1998 The nuclear vitamin D
receptor: biological and molecular regulatory properties revealed.
J Bone Miner Res 13:32549[Medline]
-
Jones G, Strugnell SA, DeLuca H 1998 Current understanding of
the molecular actions of vitamin D. Physiol Rev 78:11931231[Abstract/Free Full Text]
-
Liu M, Lee M-H, Cohen M, Bommakanti M, Freedman LP 1996 Transcriptional activation of the Cdk inhibitor p21 by vitamin
D3 leads to the induced differentiation of the
myelomonocytic cell line U937. Genes Dev 10:142153[Abstract]
-
Zhuang S-H, Bernstein KL 1998 Antiproliferative effect of
1
, 25-dihydroxyvitamin D3 in human prostate cancer cell line
LNCaP involves reduction of cyclin-dependent kinase 2 activity and
persistent G1 accumulation. Endocrinology 139:11971207[Abstract/Free Full Text]
-
Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump
DL, Johnson CS 1999 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits
the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1)
in vitro and in vivo. Cancer Res 59:26442649[Abstract/Free Full Text]
-
Campbell MJ, Koeffler HP 1997 Toward therapeutic intervention
of cancer by vitamin D compounds. J Natl Cancer Inst 89:182185[Free Full Text]
-
Colston K, Mackay AG, James AY, Binderup L 1992 EB1089: a new
vitamin D3 analog that inhibits the growth of
breast cancer cells in vivo and in vitro. Biochem Pharmacol 44:22732280[CrossRef][Medline]
-
VanWeelden K, Flanagan L, Binderup L, Tenniswood M, Welsh J 1998 Apoptotic Regression of MCF-7 xenografts in nude mice treated with
the vitamin D3 analog EB1089. Endocrinology 139:21022110[Abstract/Free Full Text]
-
Hansen CM, Hamberg KJ, Binderup E, Binderup L 2000 Seocalcitol
(EB 1089): a vitamin D analogue of anti-cancer
potential. Background, design, synthesis, pre-clinical and clinical
evaluation. Curr Pharm Design 6:803828[Medline]
-
Vokes EE, Weichselbaum RR, Lippman SM, Hong WK 1993 Head and
neck cancer. N Engl J Med 328:184194[Free Full Text]
-
Hong WK, Lippman SM, Wolf GT 1994 Recent advances in head and
neck cancer -larynx preservation and cancer chemoprevention. Cancer Res 53:51135120[Medline]
-
Hong WK, Lippman SM. Itri LM, Karp DD, Lee JS, Byers RM,
Schantz SP, Kramer AM, Lotan R, Peters LJ, Dimery IW, Brown BW,
Goepfert H 1990 Prevention of second primary tumors with isotretinoin
in squamous cell carcinoma of the head and neck. N Engl J Med 323:795801[Abstract]
-
Hu L, Crowe DL, Rheinwald JG, Chambon P, Gudas LJ 1991 Abnormal expression of retinoid receptors and keratin 19 by human oral
and epidermal squamous cell carcinoma lines. Cancer Res 51:39723981[Abstract]
-
Crowe DL 1998 Retinoic acid receptor ß induces terminal
differentiation of squamous cell carcinoma lines in the absence of
cyclin-dependent kinase inhibitor expression. Cancer Res 58:142148[Abstract]
-
Lotan R 1994 Suppression of squamous cell carcinoma growth and
differentiation by retinoids. Cancer Res 54:1987s1990s
-
Oridate N, Esumi N, Lotan D, Hong WK, Rochette-Egly C, Chambon
P, Lotan R 1996 Implication of retinoic acid receptor
in
squamous differentiation and response to retinoic acid in head and neck
SqCC/Y1 squamous carcinoma cells. Oncogene 12:20192028[Medline]
-
Lotan R 1997 Roles of retinoids and their receptors in the
development and prevention of upper aerodigestive tract cancers.
Environ Health Perspect 105:985988[Medline]
-
McGregor F, Wagner E, Felix D, Soutar D, Parkinson K, Harrison
PR 1997 Inappropriate retinoic acid receptor-ß expression in
oral dysplasias: correlation with acquisition of the immortal
phenotype. Cancer Res 57:38863889[Abstract]
-
Ferrara J, McCuaig KA, Hendy GN, Uskokovic M, White JH 1994 Highly potent transcriptional activation by 16-ene derivatives of
1,25-dihydroxyvitamin D3: lack of modulation by
9-cis retinoic acid of the response to vitamin D3
or its derivatives. J Biol Chem 269:29712981[Abstract/Free Full Text]
-
Zou A, Elgort MG, Allegretto EA 1997 Retinoid X receptor (RXR)
ligands activate the human 25-hydroxyvitamin
D3-24-hydroxylase promoter via RXR heterodimer
binding to two vitamin D3-responsive elements and
elicit additive effects with 1,25-dihydroxyvitamin
D3. J Biol Chem 272:1902719034[Abstract/Free Full Text]
-
Munker R, Kobayashi T, Elstner E, Norman AW, Uskokovic M,
Zhang W, Andreeff M, Koeffler HP 1996 A new series of vitamin D analogs
is highly active for clonal inhibition, differentiation and induction
of WAF1 in myeloid leukemia. Blood 88:22012209[Abstract/Free Full Text]
-
Zhuang, S-H, Bernstein KL 1998 Antiproliferative effect of
1
, 25-dihydroxyvitamin D3 in human
prostate cancer cell line LNCaP involves reduction of cyclin-dependent
kinase 2 activity and persistent G1 accumulation. Endocrinology 139:11971207[Abstract/Free Full Text]
-
Kawa S, Nikaido T, Zhai Y, Furihata K, Fujii S, Kiyosawa K 1997 Vitamin D analogs up-regulate p21 and p27 during growth inhibition
of pancreatic carcinoma cells. Br J Cancer 76:884889[Medline]
-
Audic S, Claverie J-M 1997 The significance of digital gene
expression profiles. Genome Res 7:986995[Abstract/Free Full Text]
-
Schuchhardt J. Beule D, Malik A, Wolski E, Eickhoff H, Lehrach
H, Herzel H 2000 Normalization strategies for cDNA microarrays. Nucleic
Acid Res 28:e47.i-v
-
Lee ML, Kuo FC, Whitmore GA, Sklar J 2000 Importance of
replication in microarray gene expression studies: statistical methods
and evidence from repetitive cDNA hybridizations. Proc Natl Acad Sci
USA 97:98349839[Abstract/Free Full Text]
-
Beißbarth T, Fellenberg K, Brors B, Arribas-Prat R, Boer JM,
Hauser NC, Scheideler M, Hoheisel JD, Schütz G, Poustka A,
Vingron M 2000 Processing and quality control of DNA array
hybridization data. Bioinformatics 16:10141022[Abstract]
-
Wang DS, Yamazaki K, Nohtomi K, Shizume K, Ohsumi K, Shibuya
M, Demura H, Sato K, 1996 Increase of vascular endothelial growth
factor mRNA expression by 1,25-dihydroxyvitamin
D3 in human osteoblast-like cells. J Bone
Miner Res 11:472479[Medline]
-
Wang DS, Miura M, Demura H, Sato K 1997 Anabolic effects of
1,25-dihydroxyvitamin D3 on osteoblasts are enhanced by vascular
endothelial growth factor produced by osteoblasts and by growth factors
produced by endothelial cells. Endocrinology 138:29532962[Abstract/Free Full Text]
-
Drittanti L, de Boland AR, Boland R 1990 Stimulation of
calmodulin synthesis in proliferating myoblasts by
1,25-dihydroxy-vitamin D3. Mol Cell Endocrinol 74:143153[CrossRef][Medline]
-
Feng X, Jiang Y, Meltzer P, Yen PM 2000 Thyroid hormone
regulation of hepatic genes in vivo detected by
complementary cDNA microarray. Mol Endocrinol 14:947955[Abstract/Free Full Text]
-
Papathanasiou MA, Kerr NC, Robbins JH, McBride OW, Alamo Jr I,
Barrett SF, Hickson ID, Fornace Jr AJ 1991 Induction by ionizing
radiation of the gadd45 gene in cultured human cells: lack of
medication by protein kinase C. Mol Cell Biol 11:10091016[Medline]
-
Zhan Q, Lord KA, Alamo I Jr, Hollander MC, Carrier F, Ron D,
Kohn KW, Hoffman B, Liebermann DA, Fornace Jr AJ 1994 The gadd and Myd
genes define a novel set of mammalian genes encoding proteins that
synergistically suppress cell growth. Mol Cell Biol 11:10091016
-
Hollander MC, Sheikh MS, Bulavin DV, Lundgren K,
Augeri-Henmueller L, Shehee R, Molinaro TA, Kim KE, Tolosa E, Ashwell
JD, Rosenberg MP, Zhan Q, Fernandez-Salguero PM, Morgan WF, Deng CX,
Fornace Jr AJ 1999 Genomic instability in Gadd45
-deficient
mice. Nat Genet 23:17684[CrossRef][Medline]
-
Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM, Kastan
MB, OConnor PM, Fornace Jr AJ 1994 Interaction of the p53-regulated
protein Gadd45 with proliferating cell nuclear antigen. Science 266:13761380[Medline]
-
Chen I-T, Smith ML, OConnor PM, Fornace Jr AJ 1995 Direct
interaction of Gadd45 with PCNA and evidence for competitive
interaction of Gadd45 and p21waf1/cip1 with PCNA.
Oncogene 11:19311937[Medline]
-
Hall PA, Kearsey JM, Coates PJ, Norman DG, Warbrick E, Cox LS 1995 Characterization of the interaction between PCNA and Gadd45.
Oncogene 10:24272433[Medline]
-
Prudencio J, Akutsu N, Wong T, Bastien Y, Lin R, Black MJ,
Alaoui-Jamali M, White JH, Action of low calcemic
1
,25-dihydroxyvitamin D3 analogue EB1089 in head and
neck squamous cell carcinoma. J Natl Cancer Inst, in press
-
Ratnam AV, Bikle DD, Su MJ, Pillai S 1996 Squamous carcinoma
cell lines fail to respond to 1,25-dihydroxyvitamin D3 despite normal
levels of the vitamin D receptor. J Invest Dermatol 106:522525[Abstract]
-
Xie Z, Bikle DD 1998 Differential regulation of vitamin D
responsive elements in normal and transformed keratinocytes. J
Invest Dermatol 110:73033[Abstract]
-
Harkin DP, Bean JM, Miklos D, Song Y-H, Troung VB, Englert C,
Christians FC, Ellisen LW, Maheswaran S, Oliner JD, Haber DA 1999 Induction of GADD45 and JNK/SAP-dependent apoptosis following inducible
expression of BRCA1. Cell 97:575586[Medline]
-
Lee SB, Huang K, Palmer R, Truong VB, Herzlinger D, Kolquist
KA, Wong J, Paulding C, Yoon SK, Gerald W, Oliner JD, Haber DA 1999 The
Wilms tumor suppressor WT1 encodes a transcriptional activator of
amphiregulin. Cell 98:66373[Medline]
-
Buse P, Tran SH, Luther E, Phu PT, Aponte GW, Firestone GL 1999 Cell cycle and hormonal control of nuclear-cytoplasmic
localization by serum- and glucocorticoid-inducible kinase, Sgk, in
mammary tumor cells. A novel convergence point of antiproliferative and
proliferative cell signaling pathways. J Biol Chem 274:725363[Abstract/Free Full Text]
-
Shivji KK, Kenny MK, Wood RD 1992 Proliferating cell nuclear
antigen is required for DNA excision repair. Cell 69:367374[Medline]
-
Smith ML, Ford JM, Hollander MC, Bortnick RA, Amundson SA, Seo
YR, Deng CX, Hanawalt PC, Fornace Jr AJ 2000 p53-mediated DNA repair
responses to UV radiation: studies of mouse cells lacking p53, p21,
and/or gadd45 genes. Mol Cell Biol 20:37053714[Abstract/Free Full Text]
-
Carrier F, Georgel PT, Pourquier P, Blake M, Kontny HU,
Antinore MJ, Gariboldi M, Myers TG, Weinstein JN, Pommier Y, Fornace Jr
AJ 1999 Gadd45, a p53-responsive stress protein, modifies DNA
accessibility on damaged chromatin. Mol Cell Biol 19:16731685[Abstract/Free Full Text]
-
Hall PA, McKee PH, Menage R, Dover D, Lane P 1993 High levels
of p53 protein in UV-irradiated normal human skin. Oncogene 8:203207[Medline]
-
Waga S, Hannon GJ, Beach D, Stillman B 1994 The p21 inhibitor
of cyclin-dependent kinases controls DNA replication by interaction
with PCNA. Nature 369:574578[CrossRef][Medline]
-
Chen IT, Smith ML, OConnor PM, Fornace AJ 1995 Direct
interaction of Gadd45 with PCNA and evidence for competitive
interaction of Gadd45 and p21Waf1/Cip1 with PCNA. Oncogene 11:19311937[Medline]
-
Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E 1999 Selective ablation of immature blood vessels in established human
tumors follows vascular endothelial growth factor withdrawal. J
Clin Invest 103:159165[Abstract/Free Full Text]
-
Eisma RJ, Spiro JD, Kreutzer DL 1997 Vascular endothelial
growth factor expression in head and neck squamous cell carcinoma.
Am J Surg 174:513517[CrossRef][Medline]
-
Takeshita A, Imai K, Kato S, Kitano S, Hanazawa S 1998 1
,25-dehydroxyvitamin D3 synergism toward
transforming growth factor-ß1-induced AP-1 transcriptional activity
in mouse osteoblastic cells via its nuclear receptor. J Biol Chem 273:1473814744[Abstract/Free Full Text]
-
Chen A, Davis BH, Bissonnette M, Scaglione-Sewell B, Brasitus
TA 1999 1,25-Dihydroxyvitamin D(3) stimulates activator
protein-1-dependent caco-2 cell differentiation. J Biol Chem 274:3550535513[Abstract/Free Full Text]
-
Johansen C, Iversen L, Ryborg A, Kragballe K 2000 1
,25-dihydroxyvitamin D3 induced
differentiation of cultured human keratinocytes is accompanied by a
PKC-independent regulation of AP-1 DNA binding activity. J Invest
Dermatol 114:11741179[Abstract/Free Full Text]
-
Kothary R, Clapoff S, Darling S, Perry MD, Moran LA, Rossant J 1994 Inducible expression of an hsp68-lacZ hybrid gene in transgenic
mice. Development 105:707714[Abstract]
-
Nordeen SK 1988 Luciferase reporter gene vectors for analysis
of promoters and enhancers. Biotechniques 6:454458[Medline]
-
Tora L, White J, Brou C, Tasset D, Webster NJG, Scheer E,
Chambon P 1989 Human estrogen receptor has two independent non-acidic
transactivation functions. Cell 59:477487[Medline]